



Cite this as: *BMJ* 2022;376:o80  
<http://dx.doi.org/10.1136/bmj.o80>  
Published: 13 January 2022

## Update to living WHO guideline on drugs for covid-19

This living guideline by Agarwal and colleagues (*BMJ* 2020;370:m3379) has been updated. For the latest update, visit doi:. The latest version of this WHO living guidance provides (a) a strong recommendation for the use of baricitinib as an alternative to interleukin-6 (IL-6) receptor blockers, in combination with corticosteroids, in patients with severe or critical covid-19; (b) a conditional recommendation against the use of ruxolitinib and tofacitinib for patients with severe or critical covid-19; (c) a conditional recommendation for the use of sotrovimab in patients with non-severe covid-19, restricted to those at highest risk of hospitalisation.